Shilpa Commissions Integrated ADC Drug Substance GMP Manufacturing Facility
India-based Shilpa Biologicals commissioned an antibody–drug conjugate (ADC) GMP manufacturing facility, purpose-built and designed to meet global regulatory approval standards including U.S. FDA, EMA, and other major health authority requirements. The facility is fully operational, with GMP qualification protocols now underway.
According to Sridevi Khambhampaty, CEO, Shilpa Biologicals, “The manufacturing of highly potent compounds has been a core pillar of Shilpa’s identity, and this ADC drug substance facility adds a new sophisticated dimension to the capabilities of the Shilpa group. We now offer global biotech and pharma partners a uniquely integrated ADC facility built with the knowledge of our existing high potency manufacturing excellence.”
“India has the scientific talent and now, with this facility, the infrastructure to be a serious and trusted partner in global ADC drug substance manufacturing,” said Vishnukant Bhutada, managing director, Shilpa Medicare. “We are ready to partner with the world’s leading oncology innovators.”
NewsBiomanufacturingConjugate vaccineDrug development (Pharmacology)Good manufacturing practiceShilpa BiologicalsPrevious article
CCRM Ireland Would Be Established to Hasten Translation of Advanced Therapies Into Patient TreatmentsNext article
Iron Accumulation Drives Neurodegeneration via Chronic Stress PathwayAlso of Interest
Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE ProgramSmarter Cell Culture Starts with Better MediaRevvity Signs Agreement to Acquire Human Cell Design10 CDMO Up & Comers 2026AI Accelerates Biomanufacturing from Discovery to TranslationPurifying Complex Therapeutics Requires Fresh ApproachesRelated Media
Boston's Bioprocessing Buzz:GENReports Live from BPI 2025Sun, Sequencing, and Spatial: Day One at AGBT 2025Boston and Bioprocessing: GEN Reports Live from the First Day at BPIGlobal Single-Use Network Support Assurance of SupplyResins Address Downstream Purification ConcernsMechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic DevelopmentTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
